Investing.com – Biotech Moderna rose sharply Friday after the National Institutes of Health (NIH) said progress with the company’s potential coronavirus vaccine continues.
- The head of the NIH said this afternoon that tests of the vaccine on mice has been free of “glitches.”
- The treatment could be ready for phase 1 clinical trials on humans in 2-1/2 months, he added.
- Shares of Moderna Inc (NASDAQ:) spiked 11%.
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.